Rationale and design of A Trial of S ertraline vs. C ognitive Behavioral Therapy for En d-stage Renal Disease Patients with D epression (ASCEND)

• Published in: Contemporary clinical trials 2015, Vol.47, p.1-11
• Main Authors: Hedayati, S. Susan, Daniel, Divya M, Cohen, Scott, Comstock, Bryan, Cukor, Daniel, Diaz-Linhart, Yaminette, Dember, Laura M, Dubovsky, Amelia, Greene, Tom, Grote, Nancy, Heagerty, Patrick, Katon, Wayne, Kimmel, Paul L, Kutner, Nancy, Linke, Lori, Quinn, Davin, Rue, Tessa, Trivedi, Madhukar H, Unruh, Mark, Weisbord, Steven, Young, Bessie A, Mehrotra, Rajnish
• Format: Article
• Language: English
• Subjects: Cardiovascular; Hematology, Oncology and Palliative Medicine
• ISSN: 1551-7144
• DOI: 10.1016/j.cct.2015.11.020

Abstract Major Depressive Disorder (MDD) is highly prevalent in patients with End Stage Renal Disease (ESRD) treated with maintenance hemodialysis (HD). Despite the high prevalence and robust data demonstrating an independent association between depression and poor clinical and patient-reported outcomes, MDD is under-treated when identified in such patients. This may in part be due to the paucity of evidence confirming the safety and efficacy of treatments for depression in this population. It is also unclear whether HD patients are interested in receiving treatment for depression. ASCEND (Clinical Trials Identifier Number NCT02358343 ), A Trial of S ertraline vs. C ognitive Behavioral Therapy (CBT) for En d-stage Renal Disease Patients with D epression, was designed as a multi-center, 12-week, open-label, randomized, controlled trial of prevalent HD patients with comorbid MDD or dysthymia. It will compare (1) a single Engagement Interview vs. a control visit for the probability of initiating treatment for comorbid depression in up to 400 patients; and (2) individual chair-side CBT vs. flexible-dose treatment with a selective serotonin reuptake inhibitor, sertraline, for improvement of depressive symptoms in 180 of the up to 400 patients. The evolution of depressive symptoms will also be examined in a prospective longitudinal cohort of 90 HD patients who choose not to be treated for depression. We discuss the rationale and design of ASCEND, the first large-scale randomized controlled trial evaluating efficacy of non-pharmacologic vs. pharmacologic treatment of depression in HD patients for patient-centered outcomes.